Title : Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Pub. Date : 2015 Mar 20

PMID : 25667274






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Patients were enrolled onto a not-otherwise-specified arm and treated with standard-of-care therapies or one of the following five biomarker-matched treatment groups: erlotinib for EGFR mutations; selumetinib for KRAS, NRAS, HRAS, or BRAF mutations; MK2206 for PIK3CA, AKT, or PTEN mutations; lapatinib for ERBB2 mutations or amplifications; and sunitinib for KIT or PDGFRA mutations or amplification. AZD 6244 KRAS proto-oncogene, GTPase Homo sapiens